FOUNDATIONONE®LIQUID CDx

PATIENT
Huang, Ching-Mao

TUMOR TYPE
Esophagus squamous cell carcinoma (SCC)

COUNTRY CODE
TW

REPORT DATE
22 June 2023

ORDERED TEST #
ORD-1651472-01

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT
DISEASE Esophagus squamous cell carcinoma (SCC)
NAME Huang, Ching-Mao
DATE OF BIRTH 23 April 1956
SEX Male
MEDICAL RECORD # 49532561

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN ID CMH 4/23/1956
SPECIMEN TYPE Blood
DATE OF COLLECTION 12 June 2023
SPECIMEN RECEIVED 15 June 2023

Biomarker Findings

Blood Tumor Mutational Burden - 3 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Elevated Tumor Fraction Not Detected

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

NF1 H1693fs*2
PIK3CA E545K
CIC S1503fs*7
RB1 rearrangement exon 17
TP53 V122fs*2

Report Highlights

- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 10)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS
Blood Tumor Mutational Burden - 3 Muts/Mb	**No therapies or clinical trials.** See Biomarker Findings section
Microsatellite status - MSI-High Not Detected	**MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).**
Tumor Fraction - Elevated Tumor Fraction Not Detected	**Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected. The fact that elevated tumor fraction was not detected in this specimen indicates the possibility of lower levels of ctDNA but does not compromise confidence in any reported alterations. However, in the setting of a negative liquid biopsy result, orthogonal testing of a tissue specimen should be considered if clinically indicated (see Biomarker Findings section).**

GENOMIC FINDINGS		VAF%	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
NF1 -	H1693fs*2	0.10%	None	None
10 Trials see p. 10				
PIK3CA -	E545K	0.14%	None	None
10 Trials see p. 12				

Electronically signed by J. Keith Killian, M.D. | 22 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC*, *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF1*, *NF2*, *PALB2*, *PMS2*, *POLE*, *PTEN*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TGFBR2*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.



HISTORIC PATIENT FINDINGS		ORD-1651472-01 VAF%
Blood Tumor Mutational Burden		3 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		Elevated Tumor Fraction Not Detected
NF1	● H1693fs*2	0.10%
PIK3CA	● E545K	0.14%
CIC	● S1503fs*7	1.6%
RB1	rearrangement exon 17	0.60%
TP53	● V122fs*2	1.0%

IMPORTANT NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. Variants reported for prior time points reflect reporting practices at the time of the historical test(s). Changes in variant reporting nomenclature, classification, or handling may result in the appearance of discrepancies across time points. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable or reportable variants may become VUS.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

Electronically signed by J. Keith Killian, M.D. | 22 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

VAF% = variant allele frequency percentage

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Please note that other aspects of this table may have changed from the previous version to reflect the most up-to-date reporting information.

BIOMARKER

Blood Tumor Mutational Burden

RESULT
3 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[1-3], anti-PD-1[3-4], anti-PD-1/CTLA4 therapies[5-6] , anti-PD-L1/CTLA4 therapies[7-10]. A Phase 2 multi-solid-tumor trial showed that bTMB ≥16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor[5]. In non-small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single-agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb-16 Muts/Mb[1,8-10]. In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[11]. In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB ≥28 Muts/Mb (approximate equivalency ≥14 Muts/Mb as measured by this assay) was associated with improved OS from a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[7].

FREQUENCY & PROGNOSIS

Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2023). For patients with squamous cell carcinoma (SCC) treated with PD-L1/PD-1 inhibitors, a Kaplan-Meier analysis showed a significant association for patients with high tumor mutational burden (TMB) with longer time to treatment failure (9.9 vs. 4.4 months)[12]. In the majority of cutaneous SCC cases, high mutational burden has been attributed to UV exposure rather than defective DNA mismatch repair or polymerase activity[13-14], although one study reported a small number of cutaneous SCC cases (4/39) harboring a mutation signature similar to that of human papillomavirus-positive head and neck SCC[14]. In patients with non-small cell lung cancer (NSCLC), TMB is similar between cases with squamous and non-squamous histology[15], and increased TMB is associated with higher tumor grade and poor prognosis[16], as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high-TMB samples each) but not BRAF (10%) or KRAS (9.4%)[15]. Although some studies have reported a lack of association between smoking and increased TMB in NSCLC[16-17], several other large studies did find a strong prognostic association[18-21]. For patients with gastric cancer, increased TMB is reported to be associated with prolonged OS[22-24]. One study observed that the OS and disease-free survival (DFS) benefits of postoperative chemotherapy were more pronounced in patients with TMB-low gastric cancer (stage Ib/II) compared to those with TMB-high; however, patients with stage III gastric cancer benefitted regardless of TMB level[25]. In esophageal cancer, patients with TMB-high who had not received radiotherapy had significantly reduced OS (p=0.038) compared to those with TMB-low[26].

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[27-28] and cigarette smoke in lung cancer[29-30], treatment with temozolomide-based chemotherapy in glioma[31-32], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[33-37], and microsatellite instability (MSI)[33,36-37]. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[1-2,4]. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

BIOMARKER

Tumor Fraction

RESULT
Elevated Tumor Fraction Not Detected

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Specimens with elevated tumor fraction values have high circulating-tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management[38-43].

FREQUENCY & PROGNOSIS

Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)[44]. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer[45], Ewing sarcoma and osteosarcoma[46], prostate cancer[41], breast cancer[47], leiomyosarcoma[48], esophageal cancer[49], colorectal cancer[50], and gastrointestinal cancer[51].

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content[52], the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy[53-54].

GENE
NF1

ALTERATION
H1693fs*2

HGVS VARIANT
NM_001042492.2:c.5078dup (p.H1693Qfs*2)

VARIANT CHROMOSOMAL POSITION
chr17:29653079

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in neurofibromatosis type 1-associated neurofibroma and malignant peripheral nerve sheath tumors[55-59], central nervous system tumors including glioma and astrocytoma[60-63], limited clinical evidence for MEK inhibitors in non-small cell lung cancer (NSCLC)[63-64], and in combination with chemotherapy for biliary tract cancers[65], NF1 inactivation may predict sensitivity to MEK inhibitors such as cobimetinib, trametinib, binimetinib, and selumetinib. On the basis of limited clinical data[66-68] and preclinical data[69-70], loss or inactivation of NF1 may predict sensitivity to mTOR inhibitors, including everolimus and temsirolimus. A preclinical study suggests that combined mTOR and MEK inhibition is effective in a model of NF1-deficient malignant peripheral nerve sheath tumors (MPNST)[71]. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.

FREQUENCY & PROGNOSIS

NF1 mutations have been detected in 4.9% of stomach adenocarcinoma cases in 1 study[72] and were not detected in any of the 151 cases of esophageal adenocarcinoma[73] and 57 cases of gastroesophageal junction carcinoma[74] analyzed in 2 other studies. In 1 study, loss of a chromosomal region that includes NF1 was found in 70% (7/10) of Barrett's adenocarcinoma samples[75]. Published data investigating the prognostic implications of NF1 alterations in esophageal carcinoma are limited (PubMed, Feb 2023). Case reports have reported patients with SCCs with neurofibromatosis type 1[76-78].

FINDING SUMMARY

NF1 encodes neurofibromin, a GTPase-activating protein (GAP) that is a key negative regulator of the RAS signaling pathway[79]. Neurofibromin acts as a tumor suppressor by repressing RAS signaling[80]. The consequences of alterations that may leave the GAP-related domain intact, such as seen here, are unclear; however, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance.

POTENTIAL GERMLINE IMPLICATIONS

Germline mutations in NF1 cause the autosomal dominant disorder neurofibromatosis type 1, which is characterized in part by increased risk of developing various tumors, including sarcoma, glioma, breast carcinoma, and neuroendocrine and hematological neoplasms[81-83]. Estimates for the prevalence of the disorder in the general population range from 1:2,500 to 1:3,000[84-85], and in the appropriate clinical context, germline testing of NF1 is recommended.

GENE
PIK3CA

ALTERATION
E545K

HGVS VARIANT
NM_006218.2:c.1633G>A (p.E545K)

VARIANT CHROMOSOMAL POSITION
chr3:178936091

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K[86-93], AKT[94-95], or mTOR[96-103]. The Phase 2 NCI-MATCH study of copanlisib for patients with refractory solid tumors harboring PIK3CA mutations with or without PTEN loss met its primary endpoint with an ORR of 16% (4/25 PRs); responses (PR or SD >6 months) were seen in patients with ameloblastoma, liposarcoma, and carcinomas of the endometrium, ovary, esophagus, lung, and prostate[93]. However, the Phase 2 study of copanlisib for patients with endometrial carcinoma harboring PIK3CA hotspot mutations failed to report any objective responses (n=11)[92]. Two other studies of copanlisib for patients with genomically unselected tumors reported 1 CR and 2 PRs (1 unconfirmed) among 16 total patients with PIK3CA-mutated solid tumors with or without PTEN alterations[90-91]. In the Phase 2 MATCH trial for patients with PIK3CA-mutated solid tumors, 28% (18/65) of patients experienced PFS lasting at least 6 months after treatment with taselisib; however, no ORs were observed in this study[104]. A separate Phase 1b study of taselisib in combination with the CDK4/6 inhibitor palbociclib for patients with PIK3CA-mutated solid tumors reported an ORR of 0% (n=12) and a DCR of 17% (2/12)[105]. In a Phase 1 trial of the dual PI3K/mTOR kinase inhibitor apitolisib, 79% (11/14) of patients with PIK3CA-mutated advanced solid tumors experienced disease control (3 PRs, 8 SDs)[106]. The PI3K inhibitor alpelisib is approved as a single agent for the treatment of patients with PIK3CA-related overgrowth spectrum (PROS)[107], but has shown limited activity as monotherapy for PIK3CA-mutated solid tumors with a Phase 1a study reporting an ORR of 6.0% (8/134) and a DCR of 58% (78/134)[87].

FREQUENCY & PROGNOSIS

PIK3CA mutation, mainly in exons 9 or 20, has been reported in 7-21% of esophageal squamous cell carcinoma (ESCC) cases[108-111]. PIK3CA amplification has been identified in 27-60% of ESCC cases, with copy number increases of six to eight fold detected[110,112-114]. In addition, increased PIK3CA mRNA has been observed in 78% of ESCC samples[110]. Expression of PIK3CA mRNA or p110-alpha protein in esophageal squamous cell carcinoma has been correlated with lymph node metastasis and poor prognosis, while PIK3CA mutation has been associated with longer survival[110-111,115].

FINDING SUMMARY

PIK3CA encodes p110-alpha, which is the catalytic subunit of phosphatidylinositol 3-kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival[116-117]. PIK3CA alterations that have been characterized as activating, such as observed here, are predicted to be oncogenic[118-139].

Electronically signed by J. Keith Killian, M.D. | 22 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
CIC

ALTERATION
S1503fs*7

HGVS VARIANT
NM_015125.4:c.4506del (p.S1503Pfs*7)

VARIANT CHROMOSOMAL POSITION
chr19:42799019-42799020

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in CIC.

FREQUENCY & PROGNOSIS

CIC mutations have been described in various solid tumors, including 1–10% of sequenced gastric, endometrial, and colorectal carcinomas and melanoma tumors (cBioPortal, COSMIC, Jan 2023)[140-142], although the consequences of CIC mutations in these tumor types have not been studied. CIC mutations have been observed in 58–69% of oligodendrogliomas but are less common in other gliomas, such as astrocytoma or oligoastrocytoma[143-145]. Published data investigating the prognostic implications of CIC alterations are generally limited (PubMed, Jun 2023). Conflicting data have been reported regarding the prognostic significance of CIC mutation in oligodendroglioma[144,146-147].

FINDING SUMMARY

CIC encodes a transcriptional repressor that plays a role in central nervous system (CNS) development[148]. CIC inactivation has been reported in various malignancies, and is highly recurrent in oligodendroglioma[143-144].

GENE
RB1

ALTERATION
rearrangement exon 17

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of limited clinical data[149] and strong preclinical data[150-153], RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer (SCLC). A clinical study evaluating the Aurora kinase A inhibitor alisertib for patients with prostate cancer did not find an association between RB1 deletion and clinical benefit[154]. Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL-2 family members[155] and activation of the NOTCH pathway[156].

FREQUENCY & PROGNOSIS

RB1 mutations have been reported in 4-8% of esophageal squamous cell carcinomas (ESCC); RB1 loss was not detected among 90 analyzed cases[157-159]. Loss of heterozygosity (LOH) of RB1 was reported in 34.7% of ESCC samples analyzed in one study[160]. RB1 promoter methylation or LOH, and subsequent loss of Rb protein expression, has been reported in 14% of laryngeal, 5% of cutaneous, 44% of esophageal, and 23% of head and neck SCC cases in the scientific literature[161-164]. Published data investigating the prognostic implications of RB1 alterations in ESCC are limited (PubMed, Mar 2023). In a study of patients with ESCC, RB1 LOH was not associated with lymph node metastasis[160].

FINDING SUMMARY

RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle[165-166]. Alterations such as seen here may disrupt RB1 function or expression[167-173].

POTENTIAL GERMLINE IMPLICATIONS

Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year[174]. Germline mutations in RB1 account for approximately 40% of RB tumors[175] and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma[176-177]. In the appropriate clinical context, germline testing of RB1 is recommended.

Electronically signed by J. Keith Killian, M.D. | 22 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
TP53

ALTERATION
V122fs*2

HGVS VARIANT
NM_000546.4:c.363_364insAT (p.V122Mfs*2)

VARIANT CHROMOSOMAL POSITION
chr17:7579323

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[178-181] or p53 gene therapy such as SGT53[182-186]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype[187]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[188]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer[189]. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[190]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel[191]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations[192]. The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring[193]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[186]. Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR[194]. A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29)[195].

FREQUENCY & PROGNOSIS

TP53 mutations have been observed in 61-93% of esophageal squamous cell carcinoma samples[158-159,196]. While some studies have reported no association between TP53 mutation status and prognosis in patients with esophageal carcinoma or gastroesophageal junction adenocarcinoma[197-198] others have associated TP53 mutation and elevated p53 expression with poor prognosis for patients with esophageal squamous cell carcinoma[199-200] or stomach cancer[201-203].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[204]. Alterations such as seen here may disrupt TP53 function or expression[205-209].

POTENTIAL GERMLINE IMPLICATIONS

Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[210-212], including sarcomas[213-214]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[215] to 1:20,000[214]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[216]. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[217-222]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[217-218]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[223]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[221,224-225]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

GENE
NF1

ALTERATION
H1693fs*2

RATIONALE
On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.

NCT03239015

PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT04985604

PHASE 1/2

DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors

TARGETS
BRAF, MEK

LOCATIONS: Busan (Korea, Republic of), Seoul (Korea, Republic of), Clayton (Australia), Edegem (Belgium), Oregon, Barcelona (Spain), Madrid (Spain), California, Colorado

NCT05125523

PHASE 1

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

TARGETS
mTOR

LOCATIONS: Tianjin (China)

NCT05580770

PHASE 1/2

Mirdametinib + BGB-3245 in Advanced Solid Tumors

TARGETS
BRAF, MEK

LOCATIONS: Waratah (Australia), Melbourne (Australia), California, Ohio, Massachusetts, Texas, Connecticut, Florida

NCT04551521

PHASE 2

CRAFT: The NCT-PMO-1602 Phase II Trial

TARGETS
PD-L1, AKTs, MEK, BRAF, ALK, RET, ERBB2

LOCATIONS: Lübeck (Germany), Würzburg (Germany), Mainz (Germany), Heidelberg (Germany), Tübingen (Germany)

NCT03297606

PHASE 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

TARGETS
VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO

LOCATIONS: Vancouver (Canada), Kelowna (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)

NCT04892017

PHASE 1/2

A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.

TARGETS
ULK1, ULK2, MEK

LOCATIONS: Oregon, Massachusetts, New York, Texas, Pennsylvania

NCT05340621

PHASE 1/2

OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

TARGETS
HDACs, MEK

LOCATIONS: California, Michigan, Massachusetts, New York, Tennessee, Virginia, Texas, Georgia, Florida

NCT04720976

PHASE 1/2

JAB-3312 Activity in Adult Patients With Advanced Solid Tumors

TARGETS
MEK, SHP2, PD-1, EGFR, KRAS

LOCATIONS: Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut

GENE
PIK3CA

ALTERATION
E545K

RATIONALE
PIK3CA activating mutations may lead to activation of the PI3K-AKT-mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA-mutated solid tumors to the PI3K-alpha inhibitor alpelisib.

NCT04589845

PHASE 2

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

TARGETS
TRKB, ALK, TRKC, ROS1, TRKA, RET, PD-L1, AKTs, ERBB2, MDM2, PI3K-alpha, RAFs, NRAS

LOCATIONS: Taipei City (Taiwan), Taoyuan County (Taiwan), Shanghai City (China), Shanghai (China), Shatin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi'an (China), Tianjin (China), Beijing City (China)

NCT03239015

PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT04526470

PHASE 1/2

Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer

TARGETS
PI3K-alpha

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of)

NCT05125523

PHASE 1

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

TARGETS
mTOR

LOCATIONS: Tianjin (China)

NCT03772561

PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

NCT04551521

PHASE 2

CRAFT: The NCT-PMO-1602 Phase II Trial

TARGETS
PD-L1, AKTs, MEK, BRAF, ALK, RET, ERBB2

LOCATIONS: Lübeck (Germany), Würzburg (Germany), Mainz (Germany), Heidelberg (Germany), Tübingen (Germany)

NCT03297606

PHASE 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

TARGETS
VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO

LOCATIONS: Vancouver (Canada), Kelowna (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)

NCT04317105

PHASE 1/2

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

TARGETS
PD-1, CTLA-4, PI3K

LOCATIONS: Toronto (Canada), Texas, Virginia

NCT04817956

PHASE 2

Improving Public Cancer Care by Implementing Precision Medicine in Norway

TARGETS
PD-L1, VEGFA, ERBB2, ALK, RET, PARP, SMO, TRKB, TRKC, ROS1, TRKA, MEK, BRAF, PI3K-alpha, FGFR1, FGFR2, FGFR3, MET, KIT, ABL

LOCATIONS: Tromsø (Norway), Bodø (Norway), Hamar (Norway), Oslo (Norway), Fredrikstad (Norway), Drammen (Norway), Trondheim (Norway), Skien (Norway), Førde (Norway), Bergen (Norway)

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

AKT3
NM_005465.3: c.1379T>A
(p.M460K)
chr1:243668612

APC
NM_000038.4: c.2992G>A
(p.G998S)
chr5:112174283

ARAF
NM_001654.3: c.690C>A
(p.N230K)
chrX:47426170

EMSY (C11ORF30)
NM_020193.3: c.2873C>T
(p.P958L)
chr11:76255466

KMT2D (MLL2)
NM_003482.4: c.14239G>A
(p.A4747T)
chr12:49422856

LTK
NM_002344.5: c.1706G>A
(p.R569H)
chr15:41797720

NTRK3
NM_002530.2: c.2033G>T
(p.R678L)
chr15:88472522

PALB2
NM_024675.3: c.3294G>C
(p.K1098N)
chr16:23619241

PARP3
NM_005485.4: c.1223G>A
(p.R408H)
chr3:51980306

PIK3C2G
NM_004570.4: c.56A>G
(p.Y19C)
chr12:18435071

RB1
NM_000321.2: c.958C>G
(p.R320G)
chr13:48941648

ORDERED TEST # ORD-1651472-01

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *) ; 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 **Exons 4-9**	*ACVR1B*	***AKT1*** **Exon 3**	*AKT2*	*AKT3*	***ALK*** **Exons 20-29, Introns 18, 19**	*ALOX12B*	*AMER1* (FAM123B or WTX)	***APC***
AR	***ARAF*** **Exons 4, 5, 7, 11, 13, 15, 16**	*ARFRP1*	*ARID1A*	*ASXL1*	***ATM***	***ATR***	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BCR** Introns 8, 13, 14	***BRAF*** **Exons 11-18,** Introns 7-10	***BRCA1*** Introns 2, 7, 8, 12, 16, 19, 20	***BRCA2*** Intron 2	*BRD4*	*BRIP1*	*BTG1*
BTG2	***BTK*** **Exons 2, 15**	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	***CCND1***	*CCND2*
CCND3	*CCNE1*	*CD22*	*CD70*	*CD74** Introns 6-8	*CD79A*	*CD79B*	***CD274*** **(PD-L1)**	*CDC73*
CDH1	***CDK12***	***CDK4***	***CDK6***	*CDK8*	*CDKN1A*	*CDKN1B*	***CDKN2A***	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	***CHEK2***	*CIC*	*CREBBP*	***CRKL***	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	***CTNNB1*** **Exon 3**	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2 **Exons 5, 17, 18**	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	***EGFR*** **Introns 7,** 15, **24-27**	*EMSY* (C11orf30)	*EP300*	*EPHA3*
EPHB1	*EPHB4*	***ERBB2***	***ERBB3*** **Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25**	*ERBB4*	*ERCC4*	*ERG*	***ERRFI1***	***ESR1*** **Exons 4-8**
*ETV4** Intron 8	*ETV5** Introns 6, 7	***ETV6**** **Introns 5, 6**	*EWSR1** Introns 7-13	***EZH2*** **Exons 4, 16, 17, 18**	*EZR** Introns 9-11	*FANCA*	*FANCC*	*FANCG*
FANCL	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*	*FGF19*	*FGF23*	*FGF3*
FGF4	*FGF6*	***FGFR1*** Introns 1, 5, **Intron 17**	***FGFR2*** Intron 1, **Intron 17**	***FGFR3*** **Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17**	*FGFR4*	*FH*	*FLCN*	*FLT1*
FLT3 **Exons 14, 15, 20**	***FOXL2***	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*	*GATA6*	*GID4* (C17orf39)	***GNA11*** **Exons 4, 5**
GNA13	***GNAQ*** **Exons 4, 5**	***GNAS*** **Exons 1, 8**	*GRM3*	*GSK3B*	*H3-3A* (H3F3A)	*HDAC1*	*HGF*	*HNF1A*
HRAS **Exons 2, 3**	*HSD3B1*	*ID3*	***IDH1*** **Exon 4**	***IDH2*** **Exon 4**	*IGF1R*	*IKBKE*	*IKZF1*	*INPP4B*
IRF2	*IRF4*	*IRS2*	*JAK1*	***JAK2*** **Exon 14**	***JAK3*** **Exons 5, 11, 12, 13, 15, 16**	*JUN*	*KDM5A*	*KDM5C*
KDM6A	*KDR*	*KEAP1*	*KEL*	***KIT*** **Exons 8, 9, 11, 12, 13, 17,** Intron 16	*KLHL6*	*KMT2A* (MLL) Introns 6, 8-11, Intron 7	*KMT2D* (MLL2)	***KRAS***

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *) ; 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

LTK	*LYN*	*MAF*	***MAP2K1*** **(MEK1) Exons 2, 3**	***MAP2K2*** **(MEK2) Exons 2-4, 6, 7**	*MAP2K4*	*MAP3K1*	*MAP3K13*	*MAPK1*
MCL1	***MDM2***	*MDM4*	*MED12*	*MEF2B*	*MEN1*	*MERTK*	***MET***	*MITF*
MKNK1	*MLH1*	***MPL*** **Exon 10**	*MRE11* (MRE11A)	*MSH2* Intron 5	*MSH3*	*MSH6*	*MST1R*	*MTAP*
MTOR **Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56**	*MUTYH*	*MYB** Intron 14	***MYC*** **Intron 1**	*MYCL* (MYCL1)	***MYCN***	***MYD88*** **Exon 4**	*NBN*	***NF1***
NF2	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2* Intron 26	*NOTCH3*	***NPM1*** **Exons 4-6, 8, 10**	***NRAS*** **Exons 2, 3**
NSD2 (WHSC1 or MMSET)	*NSD3* (WHSC1L1)	*NT5C2*	***NTRK1*** **Exons 14, 15, Introns 8-11**	*NTRK2* Intron 12	***NTRK3*** **Exons 16, 17**	*NUTM1** Intron 1	*P2RY8*	***PALB2***
PARP1	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1* (PD-1)	***PDCD1LG2*** **(PD-L2)**	***PDGFRA*** **Exons 12, 18, Introns 7, 9, 11**	***PDGFRB*** **Exons 12-21, 23**
PDK1	*PIK3C2B*	*PIK3C2G*	***PIK3CA*** **Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)**	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*	*POLD1*
POLE	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PRKN* (PARK2)	*PTCH1*
PTEN	***PTPN11***	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	***RAF1*** **Exons 3, 4, 6, 7, 10, 14, 15, 17,** Introns 4-8	*RARA* Intron 2	***RB1***	*RBM10*	*REL*	***RET*** Introns 7, 8, **Exons 11, 13-16, Introns 9-11**
RICTOR	*RNF43*	***ROS1*** **Exons 31, 36-38, 40, Introns 31-35**	*RPTOR*	*RSPO2** Intron 1	*SDC4** Intron 2	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SLC34A2** Intron 4	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*
SMO	*SNCAIP*	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*
STAT3	***STK11***	*SUFU*	*SYK*	*TBX3*	*TEK*	*TENT5C* (FAM46C)	*TERC** ncRNA	***TERT**** **Promoter**
TET2	*TGFBR2*	*TIPARP*	*TMPRSS2** Introns 1-3	*TNFAIP3*	*TNFRSF14*	***TP53***	*TSC1*	*TSC2*
TYRO3	*U2AF1*	***VEGFA***	*VHL*	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status
Blood Tumor Mutational Burden (bTMB)
Tumor Fraction

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.

CE IVD

ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also reports tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF THERAPIES AND CLINICAL TRIALS

Ranking of Therapies in Summary Table
Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials
Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.
8. Tumor fraction is the percentage of circulating tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from the observed level of aneuploidy in the sample. Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected and is significantly distinct from that typically found in non-tumor samples.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*,

KMT2D (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, *TP53*, and *U2AF1*.

11. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.
12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, ATM, CBL, CHEK2, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7.9.0

1. Gandara DR, et al. Nat. Med. (2018) pmid: 30082870
2. Wang Z, et al. JAMA Oncol (2019) pmid: 30816954
3. Sturgill EG, et al. Oncologist (2022) pmid: 35274716
4. Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950
5. Schenker et al., 2022; AACR Abstract CT022
6. Saori et al., 2021; ESMO Abstract 80P
7. Chen EX, et al. JAMA Oncol (2020) pmid: 32379280
8. Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377
9. Si H, et al. Clin Cancer Res (2021) pmid: 33355200
10. Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700
11. Li et al., 2020; ASCO Abstract 6511
12. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31003990
13. South AP, et al. J. Invest. Dermatol. (2014) pmid: 24662767
14. Pickering CR, et al. Clin. Cancer Res. (2014) pmid: 25303977
15. Spigel et al., 2016; ASCO Abstract 9017
16. Xiao D, et al. Oncotarget (2016) pmid: 27009843
17. Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269
18. Govindan R, et al. Cell (2012) pmid: 22980976
19. Ding L, et al. Nature (2008) pmid: 18948947
20. Imielinski M, et al. Cell (2012) pmid: 22980975
21. Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028
22. Cai L, et al. Cancer Commun (Lond) (2020) pmid: 32141230
23. Zhao DY, et al. World J Gastrointest Oncol (2021) pmid: 33510848
24. Wei XL, et al. Ther Adv Med Oncol (2021) pmid: 33613701
25. Wang D, et al. Gastric Cancer (2021) pmid: 33687617
26. Yuan C, et al. Aging (Albany NY) (2020) pmid: 32165590
27. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
28. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
29. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
30. Rizvi NA, et al. Science (2015) pmid: 25765070
31. Johnson BE, et al. Science (2014) pmid: 24336570
32. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
33. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
34. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
35. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
36. Nature (2012) pmid: 22810696
37. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
38. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679
39. Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454
40. Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573
41. Choudhury AD, et al. JCI Insight (2018) pmid: 30385733
42. Goodall J, et al. Cancer Discov (2017) pmid: 28450425
43. Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207
44. Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385
45. Lapin M, et al. J Transl Med (2018) pmid: 30400802
46. Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550
47. Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117
48. Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095
49. Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681
50. Fan G, et al. PLoS ONE (2017) pmid: 28187169
51. Vu et al., 2020; DOI: 10.1200/PO.19.00204
52. Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320
53. Zhang EW, et al. Cancer (2020) pmid: 32757294
54. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418
55. Dombi E, et al. N. Engl. J. Med. (2016) pmid: 28029918
56. Schalkwijk S, et al. Cancer Chemother Pharmacol (2021) pmid: 33903938
57. Hitchen N, et al. Case Rep Oncol (2023) pmid: 36743881
58. Nagabushan S, et al. NPJ Precis Oncol (2021) pmid: 33580196
59. Hones K, et al. BMJ Case Rep (2022) pmid: 36192032
60. Fangusaro J, et al. Lancet Oncol. (2019) pmid: 31151904
61. Manoharan N, et al. J Neurooncol (2020) pmid: 32780261
62. Awada G, et al. Case Rep Oncol () pmid: 33082744
63. Wisinski KB, et al. JCO Precis Oncol (2023) pmid: 37053535
64. Middleton G, et al. Nature (2020) pmid: 32669708
65. Lowery MA, et al. Clin. Cancer Res. (2019) pmid: 30563938
66. Lim SM, et al. Oncotarget (2016) pmid: 26859683
67. Weiss B, et al. Neuro-oncology (2015) pmid: 25314964
68. Janku F, et al. Oncotarget (2014) pmid: 24931142
69. Johannessen CM, et al. Curr. Biol. (2008) pmid: 18164202
70. Johannessen CM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15937108
71. Malone CF, et al. Cancer Discov (2014) pmid: 24913553
72. Nature (2014) pmid: 25079317
73. Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077
74. Janjigian YY, et al. Cancer Discov (2018) pmid: 29122777
75. Dunn J, et al. Oncogene (1999) pmid: 10023674
76. Ishida M, et al. Oncol Lett (2013) pmid: 24137429
77. Friedrich RE, et al. Anticancer Res. (2012) pmid: 22593504
78. Musella A, et al. Case Rep Obstet Gynecol (2013) pmid: 24167749
79. Hattori S, et al. Biochem. Biophys. Res. Commun. (1991) pmid: 1904223
80. Morcos P, et al. Mol. Cell. Biol. (1996) pmid: 8628317
81. Jett K, et al. Genet. Med. (2010) pmid: 20027112
82. Patil S, et al. Oncologist (2012) pmid: 22240541
83. Evans DG, et al. Clin Sarcoma Res (2012) pmid: 23036231
84. Upadhyaya M, et al. J. Med. Genet. (1995) pmid: 8544190
85. Williams VC, et al. Pediatrics (2009) pmid: 19117870
86. Fritsch C, et al. Mol. Cancer Ther. (2014) pmid: 24608574
87. Juric D, et al. J. Clin. Oncol. (2018) pmid: 29401002
88. Gallant JN, et al. NPJ Precis Oncol (2019) pmid: 30793038
89. Delestre F, et al. Sci Transl Med (2021) pmid: 34613809
90. Morschhauser F, et al. Mol Cancer Ther (2020) pmid: 31619463
91. Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108
92. Santin AD, et al. Gynecol Oncol Rep (2020) pmid: 31934607
93. Damodaran S, et al. J Clin Oncol (2022) pmid: 35133871
94. André F, et al. N. Engl. J. Med. (2019) pmid: 31091374
95. Smyth LM, et al. NPJ Breast Cancer (2021) pmid: 33863913
96. Varnier R, et al. Eur J Cancer (2019) pmid: 31351267
97. Basse C, et al. JCO Precis Oncol (2018) pmid: 32914004
98. Sultova E, et al. Arch Gynecol Obstet (2021) pmid: 33277683
99. Mackay HJ, et al. Cancer (2014) pmid: 24166148
100. Myers AP, et al. Gynecol. Oncol. (2016) pmid: 27016228
101. Dhami J, et al. Cold Spring Harb Mol Case Stud (2018) pmid: 29588307
102. Harris EJ, et al. Front Oncol (2019) pmid: 30863722
103. Hanna GJ, et al. Clin Cancer Res (2018) pmid: 29301825
104. Krop et al., 2018; ASCO Abstract 101
105. Pascual J, et al. Cancer Discov (2021) pmid: 32958578
106. Dolly SO, et al. Clin. Cancer Res. (2016) pmid: 26787751
107. Canaud et al., 2021; ESMO Abstract LBA23
108. Maeng CH, et al. PLoS ONE (2012) pmid: 22870241
109. Phillips WA, et al. Int. J. Cancer (2006) pmid: 16380997
110. Akagi I, et al. Int. J. Oncol. (2009) pmid: 19212681
111. Shigaki H, et al. Clin. Cancer Res. (2013) pmid: 23532889
112. Bandla S, et al. Ann. Thorac. Surg. (2012) pmid: 22450065
113. Yen CC, et al. World J. Gastroenterol. (2005) pmid: 15761962
114. Yen CC, et al. Int. J. Oncol. (2003) pmid: 12963965
115. Wada S, et al. Ann. Surg. Oncol. (2006) pmid: 16788758
116. Samuels Y, et al. Cancer Cell (2005) pmid: 15950905
117. Nat. Rev. Cancer (2009) pmid: 19629070
118. Kang S, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15647370
119. Ikenoue T, et al. Cancer Res. (2005) pmid: 15930273
120. Gymnopoulos M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17376864
121. Horn S, et al. Oncogene (2008) pmid: 18317450
122. Rudd ML, et al. Clin. Cancer Res. (2011) pmid: 21266528
123. Hon WC, et al. Oncogene (2012) pmid: 22120714
124. Burke JE, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22949682
125. Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19915146
126. Laurenti R, et al. Rev Saude Publica (1990) pmid: 2103068
127. Dan S, et al. Cancer Res. (2010) pmid: 20530683
128. Oda K, et al. Cancer Res. (2008) pmid: 18829572
129. Zhao L, et al. Oncogene (2008) pmid: 18794883
130. Lui VW, et al. Cancer Discov (2013) pmid: 23619167
131. Ross RL, et al. Oncogene (2013) pmid: 22430209
132. Rivière JB, et al. Nat. Genet. (2012) pmid: 22729224
133. Shibata T, et al. Cancer Lett. (2009) pmid: 19394761
134. Dogruluk T, et al. Cancer Res. (2015) pmid: 26627007
135. Croessmann S, et al. Clin. Cancer Res. (2018) pmid: 29284706
136. Ng PK, et al. Cancer Cell (2018) pmid: 29533785
137. Spangle JM, et al. (2020) pmid: 32929011
138. Chen L, et al. Nat Commun (2018) pmid: 29636477
139. Jin N, et al. J Clin Invest (2021) pmid: 34779417
140. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
141. Gao J, et al. Sci Signal (2013) pmid: 23550210
142. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
143. Bettegowda C, et al. Science (2011) pmid: 21817013
144. Yip S, et al. J. Pathol. (2012) pmid: 22072542
145. Sahm F, et al. Acta Neuropathol. (2012) pmid: 22588899
146. Jiao Y, et al. Oncotarget (2012) pmid: 22869205
147. Chan AK, et al. Mod. Pathol. (2014) pmid: 24030748
148. Lee CJ, et al. Brain Res. Mol. Brain Res. (2002) pmid: 12393275
149. Owonikoko et al., 2016; ESMO Abstract 14230

150. Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631
151. Gong X, et al. Cancer Discov (2019) pmid: 30373917
152. Oser MG, et al. Cancer Discov (2019) pmid: 30373918
153. Yang W, et al. Kaohsiung J Med Sci (2022) pmid: 34741392
154. Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224
155. Allaman-Pillet N, et al. Ophthalmic Genet. () pmid: 21955141
156. Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955
157. Cancer Genome Atlas Research Network, et al. Nature (2017) pmid: 28052061
158. Lin DC, et al. Nat. Genet. (2014) pmid: 24686850
159. Song Y, et al. Nature (2014) pmid: 24670651
160. Harada H, et al. Cancer Res. (1999) pmid: 10446988
161. Murao K, et al. Br. J. Dermatol. (2006) pmid: 17034532
162. Ling Y, et al. J. Clin. Pathol. (2011) pmid: 21169275
163. Venugopalan M, et al. Cancer Genet. Cytogenet. (1998) pmid: 9666806
164. Rafferty M, et al. Eur Arch Otorhinolaryngol (2008) pmid: 18172658
165. Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841
166. Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056
167. Berge EO, et al. Mol. Cancer (2010) pmid: 20594292
168. Giacinti C, et al. Oncogene (2006) pmid: 16936740
169. Otterson GA, et al. Proc. Natl. Acad. Sci. U.S.A. (1997) pmid: 9342358
170. Otterson GA, et al. Am. J. Hum. Genet. (1999) pmid: 10486322
171. Qin XQ, et al. Genes Dev. (1992) pmid: 1534305
172. Rubin SM, et al. Cell (2005) pmid: 16360038
173. Sun H, et al. Mol. Cell. Biol. (2006) pmid: 16449662
174. Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159
175. Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621
176. Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478
177. Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033
178. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
179. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
180. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100
181. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
182. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
183. Xu L, et al. Mol. Med. (2001) pmid: 11713371
184. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
185. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
186. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628
187. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
188. Moore et al., 2019; ASCO Abstract 5513
189. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
190. Oza et al., 2015; ASCO Abstract 5506
191. Lee J, et al. Cancer Discov (2019) pmid: 31315834
192. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
193. Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072
194. Gourley et al., 2016; ASCO Abstract 5571
195. Park H, et al. ESMO Open (2022) pmid: 36084396
196. Sawada G, et al. Gastroenterology (2016) pmid: 26873401
197. Sengpiel C, et al. Cancer Invest. (2009) pmid: 19160092
198. Pühringer-Oppermann F, et al. J. Cancer Res. Clin. Oncol. (2006) pmid: 16538517
199. Han U, et al. Dis. Esophagus (2007) pmid: 17760650
200. Yamasaki M, et al. Ann. Surg. Oncol. (2010) pmid: 19941080
201. Liu X, et al. PLoS ONE (2012) pmid: 23285001
202. Wiksten JP, et al. Anticancer Res. () pmid: 18751407
203. Migliavacca M, et al. J. Cell. Physiol. (2004) pmid: 15254976
204. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
205. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
206. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
207. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
208. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
209. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
210. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
211. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
212. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
213. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
214. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
215. Lalloo F, et al. Lancet (2003) pmid: 12672316
216. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713
217. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
218. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
219. Xie M, et al. Nat. Med. (2014) pmid: 25326804
220. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
221. Severson EA, et al. Blood (2018) pmid: 29678827
222. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
223. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
224. Chabon JJ, et al. Nature (2020) pmid: 32269342
225. Razavi P, et al. Nat. Med. (2019) pmid: 31768066

Electronically signed by J. Keith Killian, M.D. | 22 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531